Prognostic analysis of thoracic esophageal carcinoma patients with stage pT2-3N0-1M0 after surgery
LIU Yanhu
XUE Dong
LI Juan
TAN Zhenguo
Abstract:Objective To investigate the survival and its related factors of the patients with pathological stage pT2-3N0-1M0 thoracic esophageal squamous cell carcinoma after resection.Methods From January 2011 to March 2014 in the Second Affiliated Hospital of Nanjing Medical University,127 patients with pathological stage pT2-3N0-1M0 thoracic esophageal squamous cell carcinoma after resection were enrolled.Kaplan-Meier analysis and Cox multivariate regression analysis were used to evaluate the postoperative survival and its related factors.Nomogram model was applied to implement for 1-,3-,5-year survival rate of individual patients.Results Until the end of follow-up,the 1-,3-,5-year survival rates and median overall survival (OS) were 81.8%,54.3%,38.4% and 40.0 months(95%CI:32.285-47.715),respectively.Cox multivariate analysis revealed that stage pT(pT2 and pT3),pN (pN0 and pN1),intravascular cancer embolus and tumor diameter(≤ 3 cm and>3 cm) were the independent factors for OS,risk ratios of pT3,pN1,intravascular cancer embolus and tumor diameter>3 cm were 2.207,2.157,1.758 and 1.607 (P<0.05).Nomogram model could accurately predict the survival rate of pathological stage pT2-3N0-1M0 thoracic esophageal squamous cell carcinoma.Conclusion The survival of thoracic esophageal squamous cell carcinoma patients with stage pT2-3N0-1M0 after radical treatment shows significantly poor prognosis,the long-term survival of which is closely related to the depth of infiltration,lymph node metastasis,intravascular cancer embolus and tumor diameter,which is worthy of further study.
Keywords:Esophagus carcinomaEsophagectomyCox's proportional hazards regression modelNomogramOverall survivalPrognosis
Publication Date:2017-01-01
Online Publishing Date:2025-08-15(First online date of this platform, not the publication date of the document)
Pages:6( 1006-1011 )
Chinese Clinical Oncology

Chinese Clinical Oncology

PKUISTIC
ISSN:1009-0460
Year, Vol.(Issue):2017,22(11)